1)Russell J, Fudge N, Greenhalgh T:The impact of public involvement in health research:what are we measuring? Why are we measuring it? Should we stop measuring it? Res Involv Engagem 6:63, 2020
2)McCoy MS, Jongsma KR, Friesen P et al:National Standards for Public Involvement in Research:missing the forest for the trees. J Med Ethics 44:801-804, 2018
3)Inomata T, Sung J, Nakamura M et al:New medical big data for P4 medicine on allergic conjunctivitis. Allergol Int 69:510-518, 2020
4)Okuda M:Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 91:288-296, 2003
5)Verlato G, Corsico A, Villani S et al:Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 111:1232-1238, 2003
6)Gupta R, Sheikh A, Strachan DP et al:Burden of allergic disease in the UK:secondary analyses of national databases. Clin Exp Allergy 34:520-526, 2004
7)Anandan C, Gupta R, Simpson CR et al:Epidemiology and disease burden from allergic disease in Scotland:analyses of national databases. J R Soc Med 102:431-442, 2009
8)Wong AHC, Barg SSN, Leung AKC:Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 3:118-127, 2009
9)Fireman P. Treatment of allergic rhinitis:effect on occupation productivity and work force costs. Allergy Asthma Proc 18:63-67, 1997
10)Friedlaender MH:Ocular allergy. Curr Opin Allergy Clin Immunol 11:477-482, 2011
11)Adachi T, Kainuma K, Asano K et al:Strategic Outlook toward 2030:Japan's research for allergy and immunology- Secondary publication. Allergol Int 69:561-570, 2020
」を用いたクラウド型大規模臨床研究.日眼会誌124:861-872,2020
13)Ellis AK, Soliman M, Steacy L et al:The Allergic Rhinitis- Clinical Investigator Collaborative(AR-CIC):nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. Allergy Asthma Clin Immunol 11:16, 2015
14)Lenon GB, Li CG, Da Costa C et al:Lack of efficacy of a herbal preparation(RCM-102)for seasonal allergic rhinitis:a double blind, randomised, placebo-controlled trial. Asia Pac Allergy 2:187-194, 2012
15)Midorikawa-Inomata A, Inomata T, Nojiri S et al:Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease. BMJ Open. doi:10.1136/bmjopen-2019-033940, 2019
16)奥田 稔・Crawford B・Juniper E・他:アレルギー性鼻炎・結膜炎QOL調査票(RQLQ)日本語版およびアレルギーによる作業能率の低下,活動性障害調査票(WPAI-AS)日本語版の開発.アレルギー52(増刊):70-86,2003
17)国立研究開発法人日本医療研究開発機構:患者・市民参画(PPI)ガイドブック〜患者と研究者の協働を目指す第一歩として〜.Available from:https://www.amed.go.jp/ppi/guidebook.html,2019
を使って開発! iOS版もアップデートして同時公開.Available from:https://www.juntendo.ac.jp/news/20200827-02.html,2020
19)Inomata T, Sung J, Nakamura M et al:Using Medical Big Data to Develop Personalized Medicine for Dry Eye Disease. Cornea 39:S39-S46, 2020